Lexaria Bioscience Corp (LEXX)

[Shawking]

It's also interesting how he was conveniently wrong about the epilepsy study. First of all it may be 'insanely expensive' to commercialize a drug, but Lexaria has repeatedly said that it's not their intention to commercialize it on their own. It's their intention to partner with a pharma company. Secondly DehydraTECH has more benefits than just the speed of absorption, it has also proven to greatly assist APIs to cross the blood brain barrier which would have obvious benefits in treating many neurological conditions including epilepsy. It's expected that CBD DehydraTECH would have greater efficacy at a lower dose and help protect the liver at the same time reducing the cost of the API.